This includes separating PRNRP into a biologically and clinically distinct entity from KRAS-mutant PRCC, and accordingly, developing tailored management strategies for each subtype within the evolving molecularly defined renal cell carcinomas [9,44]. The gene discussed is KRAS; the disease is renal cell carcinoma.